tiprankstipranks
MannKind Corporation (MNKD)
NASDAQ:MNKD
US Market
MNKD
MannKind
RESEARCH TOOLSreports
Want to see MNKD full AI Analyst Report?

MannKind (MNKD) Stock Forecast & Price Target

2,086 Followers
See the Price Targets and Ratings of:

MNKD Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
MannKind
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MNKD Stock 12 Month Forecast

Average Price Target

$7.54
▲(165.34% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for MannKind in the last 3 months. The average price target is $7.54 with a high forecast of $10.00 and a low forecast of $4.75. The average price target represents a 165.34% change from the last price of $2.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5357142857142865,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.3907692307692305,3.941538461538461,4.492307692307692,5.043076923076923,5.593846153846154,6.144615384615385,6.695384615384615,7.246153846153846,7.796923076923077,8.347692307692308,8.89846153846154,9.44923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.201208791208791,3.5624175824175826,3.923626373626374,4.284835164835165,4.646043956043957,5.007252747252748,5.368461538461538,5.729670329670331,6.090879120879121,6.452087912087913,6.813296703296704,7.174505494505495,{"y":7.5357142857142865,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,2.986923076923077,3.1338461538461537,3.2807692307692307,3.4276923076923076,3.5746153846153845,3.7215384615384615,3.8684615384615384,4.015384615384615,4.162307692307692,4.309230769230769,4.456153846153846,4.603076923076923,{"y":4.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.035,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$7.54Lowest Price Target$4.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on MNKD
Gregory Renza
Truist Financial
Truist Financial
$6
Buy
111.27%
Upside
Reiterated
05/07/26
Truist Financial Reaffirms Their Buy Rating on MannKind (MNKD)
Mizuho Securities Analyst forecast on MNKD
Anthony Petrone
Mizuho Securities
Mizuho Securities
$8→$7
Buy
146.48%
Upside
Reiterated
05/07/26
MannKind price target lowered to $7 from $8 at MizuhoMannKind price target lowered to $7 from $8 at Mizuho
RBC Capital Analyst forecast on MNKD
Douglas Miehm
RBC Capital
RBC Capital
$3.5→$4.75
Hold
67.25%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), United Therapeutics (NASDAQ: UTHR) and MannKind (NASDAQ: MNKD)
H.C. Wainwright Analyst forecast on MNKD
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$8→$10
Buy
252.11%
Upside
Reiterated
05/07/26
MannKind price target raised to $10 from $8 at H.C. WainwrightMannKind price target raised to $10 from $8 at H.C. Wainwright
Wells Fargo Analyst forecast on MNKD
Benjamin Burnett
Wells Fargo
Wells Fargo
$8→$10
Buy
252.11%
Upside
Reiterated
05/07/26
MannKind price target raised to $10 from $8 at Wells FargoMannKind price target raised to $10 from $8 at Wells Fargo
Wedbush Analyst forecast on MNKD
Yun Zhong
Wedbush
Wedbush
$8
Buy
181.69%
Upside
Reiterated
05/06/26
MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
Raymond James Analyst forecast on MNKD
Tiago Fauth
Raymond James
Raymond James
$8→$7
Buy
146.48%
Upside
Reiterated
02/27/26
MannKind price target lowered to $7 from $8 at Wells FargoMannKind price target lowered to $7 from $8 at Wells Fargo
Leerink Partners Analyst forecast on MNKD
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (NASDAQ: MDLN) and MannKind (NASDAQ: MNKD)
Jefferies Analyst forecast on MNKD
Faisal Khurshid
Jefferies
Jefferies
$9
Buy
216.90%
Upside
Initiated
10/10/25
MannKind (MNKD) Receives a Buy from Leerink Partners
William Blair Analyst forecast on MNKD
Steven Lichtman
William Blair
William Blair
$12→$15
Buy
428.17%
Upside
Reiterated
09/05/25
MannKind price target raised to $15 from $12 at OppenheimerMannKind price target raised to $15 from $12 at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on MNKD
Gregory Renza
Truist Financial
Truist Financial
$6
Buy
111.27%
Upside
Reiterated
05/07/26
Truist Financial Reaffirms Their Buy Rating on MannKind (MNKD)
Mizuho Securities Analyst forecast on MNKD
Anthony Petrone
Mizuho Securities
Mizuho Securities
$8→$7
Buy
146.48%
Upside
Reiterated
05/07/26
MannKind price target lowered to $7 from $8 at MizuhoMannKind price target lowered to $7 from $8 at Mizuho
RBC Capital Analyst forecast on MNKD
Douglas Miehm
RBC Capital
RBC Capital
$3.5→$4.75
Hold
67.25%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), United Therapeutics (NASDAQ: UTHR) and MannKind (NASDAQ: MNKD)
H.C. Wainwright Analyst forecast on MNKD
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$8→$10
Buy
252.11%
Upside
Reiterated
05/07/26
MannKind price target raised to $10 from $8 at H.C. WainwrightMannKind price target raised to $10 from $8 at H.C. Wainwright
Wells Fargo Analyst forecast on MNKD
Benjamin Burnett
Wells Fargo
Wells Fargo
$8→$10
Buy
252.11%
Upside
Reiterated
05/07/26
MannKind price target raised to $10 from $8 at Wells FargoMannKind price target raised to $10 from $8 at Wells Fargo
Wedbush Analyst forecast on MNKD
Yun Zhong
Wedbush
Wedbush
$8
Buy
181.69%
Upside
Reiterated
05/06/26
MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
Raymond James Analyst forecast on MNKD
Tiago Fauth
Raymond James
Raymond James
$8→$7
Buy
146.48%
Upside
Reiterated
02/27/26
MannKind price target lowered to $7 from $8 at Wells FargoMannKind price target lowered to $7 from $8 at Wells Fargo
Leerink Partners Analyst forecast on MNKD
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (NASDAQ: MDLN) and MannKind (NASDAQ: MNKD)
Jefferies Analyst forecast on MNKD
Faisal Khurshid
Jefferies
Jefferies
$9
Buy
216.90%
Upside
Initiated
10/10/25
MannKind (MNKD) Receives a Buy from Leerink Partners
William Blair Analyst forecast on MNKD
Steven Lichtman
William Blair
William Blair
$12→$15
Buy
428.17%
Upside
Reiterated
09/05/25
MannKind price target raised to $15 from $12 at OppenheimerMannKind price target raised to $15 from $12 at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MannKind

3 Months
Steven LichtmanWilliam Blair
Success Rate
14/19 ratings generated profit
74%
Average Return
+22.15%
Copying Steven Lichtman's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +22.15% per trade.
1 Year
Steven LichtmanWilliam Blair
Success Rate
12/19 ratings generated profit
63%
Average Return
+66.72%
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +66.72% per trade.
2 Years
Steven LichtmanWilliam Blair
Success Rate
13/19 ratings generated profit
68%
Average Return
+49.89%
Copying Steven Lichtman's trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +49.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNKD Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
9
8
9
10
9
Buy
6
5
4
2
1
Hold
0
1
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
14
14
15
13
In the current month, MNKD has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MNKD average Analyst price target in the past 3 months is 7.54.
Each month's total comprises the sum of three months' worth of ratings.

MNKD Financial Forecast

MNKD Earnings Forecast

Next quarter’s earnings estimate for MNKD is -$0.01 with a range of -$0.04 to $0.10. The previous quarter’s EPS was -$0.05. MNKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MNKD has Performed in-line its overall industry.
Next quarter’s earnings estimate for MNKD is -$0.01 with a range of -$0.04 to $0.10. The previous quarter’s EPS was -$0.05. MNKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MNKD has Performed in-line its overall industry.

MNKD Sales Forecast

Next quarter’s sales forecast for MNKD is $108.83M with a range of $101.50M to $115.00M. The previous quarter’s sales results were $90.17M. MNKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MNKD has Performed in-line its overall industry.
Next quarter’s sales forecast for MNKD is $108.83M with a range of $101.50M to $115.00M. The previous quarter’s sales results were $90.17M. MNKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MNKD has Performed in-line its overall industry.

MNKD Stock Forecast FAQ

What is MNKD’s average 12-month price target, according to analysts?
Based on analyst ratings, MannKind Corporation’s 12-month average price target is 7.54.
    What is MNKD’s upside potential, based on the analysts’ average price target?
    MannKind Corporation has 165.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MNKD a Buy, Sell or Hold?
          MannKind Corporation has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is MannKind Corporation’s price target?
            The average price target for MannKind Corporation is 7.54. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $4.75. The average price target represents 165.34% Increase from the current price of $2.84.
              What do analysts say about MannKind Corporation?
              MannKind Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of MNKD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.